Loading…
Loading…
BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m.
With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even opens.
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday midday after the company reported Q2 2026 results that paired a solid revenue beat with the first quarter of company-wide profitability in its history.
Legend Biotech NASDAQ: LEGN reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company's first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call.
Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report)'s share price gapped down prior to trading on Monday after Royal Bank Of Canada lowered their price target on the stock from $63.00 to $59.00. The stock had previously closed at $22.22, but opened at $20.55. Royal Bank Of Canada currently has an outperform rating
BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective as of July 24, 2026. Dr. Huang will remain as an advisor through August to support a smooth transition.
On July 15, J&J, a Legend Biotech Corporation partner, announced continued strong demand for Carvykti. Sales of this CAR-T cell therapy were $657 million in the second quarter, up 10.1% quarter-on-quarter and 49.7% year-on-year. Legend hasn't yet announced when it will publish its second-quarter report, but given Carvykti's sales, I expect it to beat consensus estimates.